Combining cell therapy with human autologous Schwann cell and bone marrow-derived mesenchymal stem cell in patients with subacute complete spinal cord injury: safety considerations and possible outcomes.
Bone-marrow-derived mesenchymal stem cell
Combination cell therapy
Schwann cells
Subacute complete spinal cord injury
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
09 08 2021
09 08 2021
Historique:
received:
22
12
2020
accepted:
12
07
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
26
8
2021
Statut:
epublish
Résumé
Cellular transplantations have promising effects on treating spinal cord injury (SCI) patients. Mesenchymal stem cells (MSCs) and Schwann cells (SCs), which have safety alongside their complementary characteristics, are suggested to be the two of the best candidates in SCI treatment. In this study, we assessed the safety and possible outcomes of intrathecal co-transplantation of autologous bone marrow MSC and SC in patients with subacute traumatic complete SCI. Eleven patients with complete SCI (American Spinal Injury Association Impairment Scale (AIS); grade A) were enrolled in this study during the subacute period of injury. The patients received an intrathecal autologous combination of MSC and SC and were followed up for 12 months. We assessed the neurological changes by the American Spinal Injury Association's (ASIA) sensory-motor scale, functional recovery by spinal cord independence measure (SCIM-III), and subjective changes along with adverse events (AE) with our checklist. Furthermore, electromyography (EMG), nerve conduction velocity (NCV), magnetic resonance imaging (MRI), and urodynamic study (UDS) were conducted for all the patients at the baseline, 6 months, and 1 year after the intervention. Light touch AIS score alterations were approximately the same as the pinprick changes (11.6 ± 13.1 and 12 ± 13, respectively) in 50% of the cervical and 63% of the lumbar-thoracic patients, and both were more than the motor score alterations (9.5 ± 3.3 in 75% of the cervical and 14% of the lumbar-thoracic patients). SCIM III total scores (21.2 ± 13.3) and all its sub-scores ("respiration and sphincter management" (15 ± 9.9), "mobility" (9.5 ± 13.3), and "self-care" (6 ± 1.4)) had statistically significant changes after cell injection. Our findings support that the most remarkable positive, subjective improvements were in trunk movement, equilibrium in standing/sitting position, the sensation of the bladder and rectal filling, and the ability of voluntary voiding. Our safety evaluation revealed no systemic complications, and radiological images showed no neoplastic overgrowth, syringomyelia, or pseudo-meningocele. The present study showed that autologous SC and bone marrow-derived MSC transplantation at the subacute stage of SCI could reveal statistically significant improvement in sensory and neurological functions among the patients. It appears that using this combination of cells is safe and effective for clinical application to spinal cord regeneration during the subacute period.
Sections du résumé
BACKGROUND
Cellular transplantations have promising effects on treating spinal cord injury (SCI) patients. Mesenchymal stem cells (MSCs) and Schwann cells (SCs), which have safety alongside their complementary characteristics, are suggested to be the two of the best candidates in SCI treatment. In this study, we assessed the safety and possible outcomes of intrathecal co-transplantation of autologous bone marrow MSC and SC in patients with subacute traumatic complete SCI.
METHODS
Eleven patients with complete SCI (American Spinal Injury Association Impairment Scale (AIS); grade A) were enrolled in this study during the subacute period of injury. The patients received an intrathecal autologous combination of MSC and SC and were followed up for 12 months. We assessed the neurological changes by the American Spinal Injury Association's (ASIA) sensory-motor scale, functional recovery by spinal cord independence measure (SCIM-III), and subjective changes along with adverse events (AE) with our checklist. Furthermore, electromyography (EMG), nerve conduction velocity (NCV), magnetic resonance imaging (MRI), and urodynamic study (UDS) were conducted for all the patients at the baseline, 6 months, and 1 year after the intervention.
RESULTS
Light touch AIS score alterations were approximately the same as the pinprick changes (11.6 ± 13.1 and 12 ± 13, respectively) in 50% of the cervical and 63% of the lumbar-thoracic patients, and both were more than the motor score alterations (9.5 ± 3.3 in 75% of the cervical and 14% of the lumbar-thoracic patients). SCIM III total scores (21.2 ± 13.3) and all its sub-scores ("respiration and sphincter management" (15 ± 9.9), "mobility" (9.5 ± 13.3), and "self-care" (6 ± 1.4)) had statistically significant changes after cell injection. Our findings support that the most remarkable positive, subjective improvements were in trunk movement, equilibrium in standing/sitting position, the sensation of the bladder and rectal filling, and the ability of voluntary voiding. Our safety evaluation revealed no systemic complications, and radiological images showed no neoplastic overgrowth, syringomyelia, or pseudo-meningocele.
CONCLUSION
The present study showed that autologous SC and bone marrow-derived MSC transplantation at the subacute stage of SCI could reveal statistically significant improvement in sensory and neurological functions among the patients. It appears that using this combination of cells is safe and effective for clinical application to spinal cord regeneration during the subacute period.
Identifiants
pubmed: 34372939
doi: 10.1186/s13287-021-02515-2
pii: 10.1186/s13287-021-02515-2
pmc: PMC8351425
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
445Informations de copyright
© 2021. The Author(s).
Références
Gene Ther. 2002 Jun;9(11):754-8
pubmed: 12032704
J Neurosci. 2014 Jan 29;34(5):1838-55
pubmed: 24478364
Stem Cells Int. 2012;2012:826754
pubmed: 23091499
Neurosci Lett. 2012 Jun 25;519(2):115-21
pubmed: 22343313
Biomed Pharmacother. 2017 Jul;91:693-706
pubmed: 28499241
Global Spine J. 2017 Sep;7(3 Suppl):175S-194S
pubmed: 29164023
Acta Biomater. 2015 Dec;28:23-32
pubmed: 26384702
Spinal Cord. 2016 Feb;54(2):102-9
pubmed: 26526896
Clin Neurol Neurosurg. 2012 Sep;114(7):935-9
pubmed: 22464434
J Neurosurg. 1993 Oct;79(4):500-7
pubmed: 8410217
Stem Cells. 2007 Aug;25(8):2066-73
pubmed: 17464087
Cell Transplant. 2008;17(12):1277-93
pubmed: 19364066
Exp Ther Med. 2013 Jul;6(1):140-146
pubmed: 23935735
Exp Neurol. 2006 Oct;201(2):335-48
pubmed: 16839548
Int J Mol Sci. 2019 May 31;20(11):
pubmed: 31159345
Am J Vet Res. 2011 Aug;72(8):1118-23
pubmed: 21801071
Int J Mol Sci. 2018 Mar 30;19(4):
pubmed: 29601528
Neurorehabil Neural Repair. 2010 Oct;24(8):702-8
pubmed: 20660620
J Neurotrauma. 2006 Mar-Apr;23(3-4):453-67
pubmed: 16629629
J Neurosci Res. 1997 Oct 15;50(2):337-44
pubmed: 9373042
Br J Neurosurg. 2011 Aug;25(4):516-22
pubmed: 21749185
Lancet Neurol. 2019 Jan;18(1):56-87
pubmed: 30497965
J Neurotrauma. 2011 Aug;28(8):1445-77
pubmed: 20030559
Brain Res. 2013 Oct 2;1533:73-9
pubmed: 23948102
Neurosurgery. 2017 Sep 1;64(CN_suppl_1):87-91
pubmed: 28899046
Cytotherapy. 2013 Jul;15(7):782-91
pubmed: 23731761
Tissue Eng. 2005 May-Jun;11(5-6):913-22
pubmed: 15998231
Neurosci Lett. 2008 Sep 26;443(1):46-50
pubmed: 18662744
Nat Neurosci. 2005 Mar;8(3):346-53
pubmed: 15711542
Cell Transplant. 2016 Nov;25(11):1925-1943
pubmed: 27075659
J Spinal Cord Med. 2008;31(3):262-9
pubmed: 18795474
Neurotherapeutics. 2011 Oct;8(4):704-20
pubmed: 22002087
Restor Neurol Neurosci. 2014;32(4):473-82
pubmed: 24670611
Stem Cells Int. 2017;2017:2374161
pubmed: 29230248
Neurosurg Focus. 2019 Mar 1;46(3):E10
pubmed: 30835679
Neurosci Lett. 2018 Mar 6;668:138-146
pubmed: 29317311
Int J Rehabil Res. 2010 Dec;33(4):356-8
pubmed: 20354443